AlzeCure Receives $10M Upfront Payment From Lilly
Stockholm, Sweden, August 18, 2026 AlzeCure Pharma AB has received the full $10 million upfront payment from Eli Lilly...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Stockholm, Sweden, August 18, 2026 AlzeCure Pharma AB has received the full $10 million upfront payment from Eli Lilly...
BOCA RATON, Fla., July 15, 2026 INmune Bio announced the publication of a peer-reviewed preclinical study in the Journal...
